Study on the difference of immune regulation effect between stereotactic radiotherapy and conventional segmented radiotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027086

Enrollment

Unknown

Registered

2019-10-31

Start date

2019-11-15

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

1:stereotactic radiotherapy

2:conventional segmentation radiotherapy

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients undergoing stereotactic radiotherapy and conventional fractionated radiotherapy.

Exclusion criteria

Exclusion criteria: Patients who do not have indications for radiotherapy.

Design outcomes

Primary

Measure	Time frame
local control;	—

Secondary

Measure	Time frame
immune effect;	—

Countries

China

Contacts

Public ContactHongqing Zhuang

Peking University Third Hospital

yiduzhengmu@163.com+86 10 82266699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026